Metabolon, Tracking Parkinson's Unite to ID Disease Progression | Groups Will Identify Biomarkers Which Could Lead to Personalized Treatments
Metabolon, Tracking Parkinson’s Unite to ID Disease Progression
Groups will identify biomarkers which could lead to personalized treatments
Metabolon is teaming up with Tracking Parkinson’s, the world’s largest long-term study into Parkinson’s disease, to identify novel metabolic biomarkers of disease progression.
The discoveries may lead to personalized treatments and better patient care.
“We are extremely enthusiastic about partnering with Tracking Parkinson’s to further the understanding of the [underlying mechanisms] of Parkinson’s disease,” Karl Bradshaw, PhD, vice-president of corporate development at …